Patents by Inventor Martha S. Hayden

Martha S. Hayden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294889
    Abstract: Compositions and methods relating to DNase fusion polypeptides are disclosed. The fusion polypeptides include a biologically active DNase joined to the amino-terminus of an immunoglobulin Fc region via a flexible polypeptide linker (e.g., a linker containing at least 26 amino acid residues). Typically, the DNase is a hyperactive and/or actin-resistant DNase1 variant (e.g., a variant of human DNase1 having one or more amino acid substitutions selected from substitutions at Asp-53, Tyr-65, Glu-69, Arg-74, Gly-105, and Ala-114 according to amino acid position numbering of mature wild-type human DNase1) or a DNase1L3 variant (e.g., a variant of human DNase1L3 in which the native nuclear localization signals are removed). In some embodiments, the fusion polypeptide includes a polypeptide segment located carboxyl-terminal to the Fc region and which may be, e.g., a biologically active paraoxonase. Also disclosed are dimeric proteins comprising first and second DNase fusion polypeptides as disclosed herein.
    Type: Application
    Filed: April 25, 2024
    Publication date: September 5, 2024
    Applicant: Theripion, Inc.
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Publication number: 20240101982
    Abstract: Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase (e.g., human PON1 or a variant thereof), wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing domain or a domain that specifically binds to the neonatal Fc receptor (FcRn)) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain.
    Type: Application
    Filed: February 17, 2022
    Publication date: March 28, 2024
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Publication number: 20230024372
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 26, 2023
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Publication number: 20230015291
    Abstract: Compositions and methods relating to DNase fusion polypeptides are disclosed. The fusion polypeptides include a biologically active DNase joined to the amino-terminus of an immunoglobulin Fc region via a flexible polypeptide linker (e.g., a linker containing at least 26 amino acid residues). Typically, the DNase is a hyperactive and/or actin-resistant DNase1 variant (e.g., a variant of human DNase1 having one or more amino acid substitutions selected from substitutions at Asp-53, Tyr-65, Glu-69, Arg-74, Gly-105, and Ala-114 according to amino acid position numbering of mature wild-type human DNase1) or a DNase1L3 variant (e.g., a variant of human DNase1L3 in which the native nuclear localization signals are removed). In some embodiments, the fusion polypeptide includes a polypeptide segment located carboxyl-terminal to the Fc region and which may be, e.g., a biologically active paraoxonase. Also disclosed are dimeric proteins comprising first and second DNase fusion polypeptides as disclosed herein.
    Type: Application
    Filed: August 11, 2022
    Publication date: January 19, 2023
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Patent number: 11472864
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: October 18, 2022
    Assignee: Theripion, Inc.
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Publication number: 20220089687
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Application
    Filed: December 3, 2021
    Publication date: March 24, 2022
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Patent number: 10307481
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: June 4, 2019
    Assignee: Aptevo Research and Development LLC
    Inventors: Laura S. Grosmaire, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter A. Thompson, Sandy A. Simon, William Brady
  • Publication number: 20180201664
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 19, 2018
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Patent number: 9101609
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: August 11, 2015
    Assignee: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Philip Tan, Sandy A Simon, Charles G Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A Ledbetter, Martha S Hayden-Ledbetter, Peter A Thompson, Cecile Morales
  • Patent number: 9005612
    Abstract: The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 14, 2015
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Publication number: 20130142793
    Abstract: The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 6, 2013
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Jeffrey A. LEDBETTER, Martha S. Hayden-Ledbetter
  • Patent number: 8106161
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
    Type: Grant
    Filed: March 23, 2005
    Date of Patent: January 31, 2012
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Publication number: 20110223164
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type lgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
    Type: Application
    Filed: March 2, 2011
    Publication date: September 15, 2011
    Applicant: Emergent Product Development Seattle, LLC
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Publication number: 20110105729
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
    Type: Application
    Filed: October 8, 2010
    Publication date: May 5, 2011
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Publication number: 20110091461
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 21, 2011
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Patent number: 7915395
    Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. In another embodiment the expression vector encodes a bispecific fusion protein, which vector comprises a recombinant bispecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen and a DNA sequence encoding a second binding domain capable of binding a cell surface antigen, each domain capable of binding a different antigen. The present invention also provides a method for producing a biologically active monospecific or bispecific fusion protein in a mammalian cell.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: March 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell, Lisa K. Gilliland
  • Publication number: 20100203052
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
    Type: Application
    Filed: March 15, 2010
    Publication date: August 12, 2010
    Applicant: Trubion Pharmaceuticals, Inc.
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Patent number: 7754208
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: July 13, 2010
    Assignee: Trubion Pharmaceuticals, Inc.
    Inventors: Jeffrey A Ledbetter, Martha S Hayden-Ledbetter
  • Publication number: 20090274692
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: April 13, 2009
    Publication date: November 5, 2009
    Applicant: Trubion Pharmaceuticals, Inc.
    Inventors: Phillip Tan, Sandy A. Simon, Charles G. Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter, Peter A. Thompson, Cecile Morales
  • Publication number: 20090214539
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: May 7, 2009
    Publication date: August 27, 2009
    Applicant: Trubion Pharmaceuticals, Inc.
    Inventors: Laura S. Grosmaire, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter A. Thompson, Sandy A. Simon, William Brady